General Information of Drug (ID: DM46F5X)

Drug Name
isobutylmethylxanthine Drug Info
Synonyms
3-Isobutyl-1-methylxanthine; IBMX; 28822-58-4; 1-METHYL-3-ISOBUTYLXANTHINE; Methylisobutylxanthine; 3-Isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione; Xanthine, 3-isobutyl-1-methyl-; 3-Isobutyl-1-methyxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-; Methyl-isobutylxanthine; 3-isobutyl-1-methylxanthine (ibmx); UNII-TBT296U68M; 3-Isobutyl 1-methylxanthine; NSC 165960; CCRIS 4290; CHEBI:34795; 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione; 3-isobutyl-1-methyl-7H-xanthine; methylisobutylxanthine; 3-Isobutyl-1-methyl-3,9-dihydro-purine-2,6-dione; 3-ISOBUTYL-1-METHYLXANTHINE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3758
ChEBI ID
CHEBI:34795
CAS Number
CAS 28822-58-4
TTD Drug ID
DM46F5X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [6]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [16]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [17]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [18]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [19]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [20]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [17]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [21]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [22]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tadalafil DMJZHT1 Benign prostatic hyperplasia GA90 Approved [23]
Udenafil DM1IQRP Erectile dysfunction HA01.1 Approved [24]
Vardenafil DMTBGW8 Cystic fibrosis CA25 Approved [25]
Dipyridamole DMXY30O Atrial fibrillation BC81.3 Approved [26]
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [27]
Avanafil DM75CXN Erectile dysfunction HA01.1 Approved [21]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [28]
ICARIIN DMOJQGT N. A. N. A. Phase 3 [29]
EXISULIND DMBY56U Colorectal cancer 2B91.Z Phase 3 [30]
PF-489791 DM3C8GQ Chronic obstructive pulmonary disease CA22 Phase 2 [31]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [16]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [32]
BI 1015550 DM6DO2P Idiopathic pulmonary fibrosis CB03.4 Phase 3 [33]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [18]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [19]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [20]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [32]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [34]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [22]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [34]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IB-MECA DM9G5XD Psoriasis vulgaris EA90 Phase 3 [35]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [36]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [37]
CF102 DMP56WJ Hepatocellular carcinoma 2C12.02 Phase 2 [38]
SCH-442416 DMQ2K1V N. A. N. A. Phase 1 [39]
AST-004 DM5WMG7 Stroke 8B20 Phase 1 [40]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [41]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [42]
CF602 DM0ULO2 Inflammation 1A00-CA43.1 Preclinical [38]
CF502 DMQSJ20 Inflammation 1A00-CA43.1 Preclinical [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Phosphodiesterase 1 (PDE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vinpocetine DMVN2E6 Ischemic stroke 8B11.5Z Approved [43]
ITI-214 DM08TH3 Parkinson disease 8A00.0 Phase 1/2 [44]
ZAPRINAST DMGH3T5 N. A. N. A. Terminated [45]
BIBW-22 DMXIH3Q Solid tumour/cancer 2A00-2F9Z Terminated [46]
S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 Discovery agent N.A. Investigative [47]
BUFROLIN DM61F5W Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dyphylline DM8DZC1 Acute bronchial asthma CA23 Approved [48]
Enprofylline DMFYZKN Asthma CA23 Approved [49]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [16]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [50]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [51]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [18]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [19]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [20]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [50]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [52]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [53]
Istradefylline DM20VSK Parkinson disease 8A00.0 Approved [54]
Regadenoson DM76VHG Radionuclide imaging N.A. Approved [21]
Tozadenant DMATC14 Parkinson disease 8A00.0 Phase 3 [55]
Binodenoson DMVHF8G Hypertension BA00-BA04 Phase 3 [56]
Apadenoson DMD8QTC Coronary artery disease BA80 Phase 3 [57]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [36]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [58]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [59]
BIIB014 DMH7RJ1 Parkinson disease 8A00.0 Phase 2 [60]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [51]
CP-461 DMEYMTX Inflammatory bowel disease DD72 Phase 2 [61]
ND7001 DMUBTC6 Mood disorder 6A60-6E23 Phase 1 [62]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [63]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD N. A. N. A. Patented [63]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL N. A. N. A. Patented [63]
Triazolo-pyridine derivative 5 DM1R205 N. A. N. A. Patented [63]
PMID27321640-Compound-58 DM0NYK3 N. A. N. A. Patented [63]
Triazolo-pyridine derivative 4 DM5ZQKS N. A. N. A. Patented [63]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 DMZ61T8 N. A. N. A. Patented [63]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [64]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [64]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [65]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [36]
YT-146 DM3YVKQ Hypertension BA00-BA04 Phase 2 [66]
AB928 DMDOXMN Metastatic colorectal cancer 2B91 Phase 1/2 [67]
KF-17837 DMQ6DLZ Parkinson disease 8A00.0 Phase 1 [68]
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [69]
CVT-6883 DMY84TW Asthma CA23 Phase 1 [70]
PBF-1129 DMOPGXM Non-small-cell lung cancer 2C25.Y Phase 1 [67]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [5]
Aminophylline DML2NIB Bronchial asthma CA23 Approved [71]
Anagrelide DMSQ8MD Thrombocythemia 3B63 Approved [72]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [73]
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [74]
BEMORADAN DMUL6GY Heart failure BD10-BD13 Phase 2 [21]
CI-930 DMADPQX N. A. N. A. Discontinued in Phase 2 [75]
EMD-53998 DMVS8IE Cardiovascular disease BA00-BE2Z Discontinued in Phase 1 [21]
IMAZODAN DMWTFO3 N. A. N. A. Terminated [76]
LAS-31180 DMW2K1L Heart failure BD10-BD13 Terminated [77]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [53]
Rolofylline DMSZPR3 Heart failure BD10-BD13 Phase 3 [78]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [36]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [59]
SELODENOSON DMQM3IX Cardiac arrhythmias BC9Z Phase 2 [79]
Apaxifylline DMQMV9F Cognitive impairment 6D71 Phase 2 [80]
SLV320 DM867BJ Heart failure BD10-BD13 Phase 2 [81]
DTI-0009 DMV84OK Atrial fibrillation BC81.3 Phase 2 [79]
Capadenoson DMYWO62 Atrial fibrillation BC81.3 Phase 2 [82]
BAY 1067197 DM4JGNH Heart failure BD10-BD13 Phase 2 [83]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [84]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [84]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [84]
Capsaicin DMGMF6V Back pain ME84.Z Approved [85]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [86]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [87]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [88]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [89]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [90]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Estrogen receptor (ESR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [91]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [92]
Gefitinib DM15F0X Colon adenocarcinoma Approved [93]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [94]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [95]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [96]
Quercetin DM3NC4M Obesity 5B81 Approved [97]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [98]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [94]
Estrone DM5T6US Acne vulgaris ED80 Approved [99]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [100]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [101]
Fructose DM43AN2 Vomiting MD90 Approved [11]
Ketoprofen DMRKXPT Bursitis Approved [11]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [102]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [103]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [104]
Gefitinib DM15F0X Colon adenocarcinoma Approved [105]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [106]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [107]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [108]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [109]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [110]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [111]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [112]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [113]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [114]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [115]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [116]
Folic Acid DMEMBJC Colorectal carcinoma Approved [117]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lipoprotein lipase (LPL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [11]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [118]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [107]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [119]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [120]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [121]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [122]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [123]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [124]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [123]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [125]
Bambuterol DMKLSHF Asthma CA23 Approved [126]
Terbutaline DMD4381 Asthma CA23 Approved [127]
Salbutamol DMN9CWF Acute asthma CA23 Approved [128]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [129]
Methotrexate DM2TEOL Anterior urethra cancer Approved [108]
Epinephrine DM3KJBC Acute asthma CA23 Approved [130]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [131]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [132]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [133]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [134]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [135]
Testosterone enanthate DMB6871 N. A. N. A. Approved [136]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [116]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [137]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [138]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [137]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [139]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [140]
Testosterone DM7HUNW Hot flushes GA30 Approved [141]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Secretogranin-2 (SCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [131]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [142]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [143]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [144]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [145]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [139]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [146]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [147]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [148]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [149]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [150]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [151]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [152]
Quercetin DM3NC4M Obesity 5B81 Approved [153]
Miglustat DM5J64S Niemann-Pick disease type C Approved [154]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [155]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [152]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [156]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [156]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [158]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [159]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [160]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [161]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [158]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [162]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [116]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [163]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [164]
Capsaicin DMGMF6V Back pain ME84.Z Approved [165]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Amphiregulin (AREG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [166]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [167]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [168]
Methotrexate DM2TEOL Anterior urethra cancer Approved [108]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [169]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [170]
Estrone DM5T6US Acne vulgaris ED80 Approved [171]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [172]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [173]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [174]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [175]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [176]
Quercetin DM3NC4M Obesity 5B81 Approved [177]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [159]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [120]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [178]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [179]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [180]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [181]
Stavudine DM6DEK9 Human immunodeficiency virus infection 1C62 Approved [182]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Adiponectin (ADIPOQ)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [183]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [183]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [184]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [185]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [183]
Cilazapril DM4V6JA Congestive heart failure BD10 Approved [186]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [187]
Stavudine DM6DEK9 Human immunodeficiency virus infection 1C62 Approved [183]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [123]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [188]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Resistin (RETN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [189]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [190]
Amlodipine DMBDAZV Angina pectoris BA40 Approved [191]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [192]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [193]
Vitamin B3 DMQVRZH Chronic renal failure GB61.Z Approved [194]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [149]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [195]
Icosapentum DMF1CM7 N. A. N. A. Investigative [196]
Sulforaphane DMQY3L0 Skin disease EA00-EM0Z Investigative [197]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [198]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [120]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [162]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [116]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [151]
Arsenic DMTL2Y1 N. A. N. A. Approved [199]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [200]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [201]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [202]
Cytarabine DMZD5QR Acute lymphoblastic leukaemia 2A85 Approved [203]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A1 receptor (ADORA1) TTK25J1 AA1R_HUMAN Antagonist [2]
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Inhibitor [3]
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Inhibitor [4]
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Inhibitor [4]
Phosphodiesterase 1 (PDE1) TTHQENC NOUNIPROTAC Inhibitor [5]
Phosphodiesterase 2A (PDE2A) TTJGW1Z PDE2A_HUMAN Inhibitor [6]
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [5]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [5]
Phosphodiesterase 4B (PDE4B) TTVIAT9 PDE4B_HUMAN Inhibitor [5]
Phosphodiesterase 4D (PDE4D) TTSKMI8 PDE4D_HUMAN Inhibitor [6]
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Gene/Protein Processing [7]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Gene/Protein Processing [8]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Gene/Protein Processing [9]
Choriogonadotropin subunit beta 3 (CGB3) OTVM2SU3 CGB3_HUMAN Protein Interaction/Cellular Processes [10]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A) OTQDYH8E ASM3A_HUMAN Drug Response [11]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [12]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [13]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Gene/Protein Processing [14]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Gene/Protein Processing [7]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Gene/Protein Processing [15]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 388).
2 Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84.
3 Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
4 Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
5 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7 Aloe-emodin inhibits adipocyte differentiation and maturation during in vitro human mesenchymal stem cell adipogenesis. J Biochem Mol Toxicol. 2012 Aug;26(8):291-300. doi: 10.1002/jbt.21415. Epub 2012 May 29.
8 The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types. Endocrinology. 2004 Nov;145(11):5177-84. doi: 10.1210/en.2004-0232. Epub 2004 Jul 29.
9 Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
10 BLTK1 murine Leydig cells: a novel steroidogenic model for evaluating the effects of reproductive and developmental toxicants. Toxicol Sci. 2012 Jun;127(2):391-402. doi: 10.1093/toxsci/kfs121. Epub 2012 Mar 29.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12 Activation of CFTR by genistein in human airway epithelial cell lines. Biochem Biophys Res Commun. 2003 Aug 29;308(3):518-22. doi: 10.1016/s0006-291x(03)01436-0.
13 Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica. 2001 Mar;31(3):135-51.
14 Evaluation of estrogen receptor alpha activation by glyphosate-based herbicide constituents. Food Chem Toxicol. 2017 Oct;108(Pt A):30-42.
15 Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol. 1991 Jul;135(2):314-25. doi: 10.1016/0008-8749(91)90276-h.
16 Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
18 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
19 Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
20 Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
22 The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
23 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
24 Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
25 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
26 Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
27 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
28 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
29 Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
30 Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
31 Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
33 BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.
34 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
35 A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
36 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
37 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
38 2011 Pipeline of Can-Fite BioPharm.
39 Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
40 Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
41 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
42 Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
43 Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
44 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
45 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
46 BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
47 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
48 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
49 Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
51 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
52 GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.
53 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
55 Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
56 Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
58 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
59 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
60 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
61 Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
62 Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
63 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
64 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
65 Clinical pipeline report, company report or official report of Klus Pharma
66 Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
67 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
68 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
69 Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
70 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
71 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
72 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
73 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
74 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
75 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
76 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
77 Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
78 Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
79 Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
81 Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
82 A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
83 Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
84 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
85 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
86 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
87 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
88 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
89 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
90 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
91 Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
92 Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
93 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
94 Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
95 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
96 Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
97 Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
98 Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
99 Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
100 Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
101 A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
102 CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
103 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
104 Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
105 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
106 Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
107 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
108 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
109 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
110 Down-regulation of interleukin-2 receptor gene activation and protein expression by dideoxynucleoside analogs. Cell Immunol. 1995 Jul;163(2):289-95. doi: 10.1006/cimm.1995.1128.
111 Ouabain induces inhibition of the progression phase in human T-cell proliferation. J Cell Physiol. 1995 Nov;165(2):246-53. doi: 10.1002/jcp.1041650205.
112 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res. 1986 Nov;46(11):5827-31.
113 Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol. 2002 Oct;130(1):85-92. doi: 10.1046/j.1365-2249.2002.01962.x.
114 Effects of different anaesthetic agents on immune cell function in vitro. Eur J Anaesthesiol. 2005 Aug;22(8):616-23. doi: 10.1017/s0265021505001031.
115 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
116 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
117 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
118 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
119 Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol. 1999 Apr;47(4):433-9. doi: 10.1046/j.1365-2125.1999.00920.x.
120 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
121 Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ Mol Mutagen. 2007 Apr-May;48(3-4):179-89. doi: 10.1002/em.20245.
122 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
123 Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
124 Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
125 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
126 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
127 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
128 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
129 Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
130 Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
131 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
132 Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
133 Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
134 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
135 The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
136 Pharmacological doses of testosterone upregulated androgen receptor and 3-Beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase and impaired leydig cells steroidogenesis in adult rats. Toxicol Sci. 2011 Jun;121(2):397-407. doi: 10.1093/toxsci/kfr063. Epub 2011 Apr 6.
137 Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
138 Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
139 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
140 Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation. Biochim Biophys Acta. 2005 Feb 21;1687(1-3):181-94. doi: 10.1016/j.bbalip.2004.11.017.
141 The inhibitory effects of manganese on steroidogenesis in rat primary Leydig cells by disrupting steroidogenic acute regulatory (StAR) protein expression. Toxicology. 2003 May 3;187(2-3):139-48. doi: 10.1016/s0300-483x(03)00063-5.
142 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
143 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
144 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
145 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
146 Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
147 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
148 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
149 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
150 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
151 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
152 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
153 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
154 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
155 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
156 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
157 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
158 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
159 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
160 Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
161 Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
162 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
163 Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
164 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
165 Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
166 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
167 Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
168 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
169 Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
170 Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
171 Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
172 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
173 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
174 Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma. Biochem Biophys Res Commun. 2001 Mar 9;281(4):1051-6. doi: 10.1006/bbrc.2001.4466.
175 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
176 Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
177 The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
178 Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
179 Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
180 Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
181 Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
182 Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
183 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
184 Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007 Jun;28(12):1440-7. doi: 10.1093/eurheartj/ehm101. Epub 2007 May 5.
185 Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
186 Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J. 2009 Dec;73(12):2282-7. doi: 10.1253/circj.cj-09-0387. Epub 2009 Sep 29.
187 Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs. Life Sci. 2020 Jun 15;251:117607. doi: 10.1016/j.lfs.2020.117607. Epub 2020 Mar 30.
188 (9)-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPAR induction: A possible evidence for the cancellation of PPAR/-mediated inhibition of PPAR in MDA-MB-231?cells. Arch Biochem Biophys. 2019 Feb 15;662:219-225. doi: 10.1016/j.abb.2018.12.011. Epub 2018 Dec 13.
189 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
190 PML-RAR interaction with TRIB3 impedes PPAR/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22):10326-10340. doi: 10.7150/thno.45924. eCollection 2020.
191 Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.
192 Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 2007 Feb;92(2):720-4.
193 Hesperetin inhibit adipocyte differentiation and enhance Bax- and p21-mediated adipolysis in human mesenchymal stem cell adipogenesis. J Biochem Mol Toxicol. 2015 Mar;29(3):99-108. doi: 10.1002/jbt.21672. Epub 2014 Oct 26.
194 Adipokines and treatment with niacin. Metabolism. 2006 Oct;55(10):1283-5. doi: 10.1016/j.metabol.2006.07.002.
195 Bisphenol A is associated with insulin resistance and modulates adiponectin and resistin gene expression in obese children. Pediatr Obes. 2017 Oct;12(5):380-387. doi: 10.1111/ijpo.12154. Epub 2016 May 17.
196 Fatty acids and expression of adipokines. Biochim Biophys Acta. 2005 May 30;1740(2):287-92. doi: 10.1016/j.bbadis.2004.11.019. Epub 2004 Dec 8.
197 Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
198 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
199 Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
200 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
201 Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
202 Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
203 Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.